Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist administered as a once-weekly injection, produces significantly greater weight loss and glycemic control in adults with obesity and type 2 diabetes compared to placebo, semaglutide, and long-acting insulin analogs.
If you have obesity and Type 2 Diabetes, standard diet and exercise may not be enough to control your blood sugar or achieve significant weight loss. Tirzepatide is a once-weekly injection that targets both GLP-1 and GIP hormones to improve insulin response, reduce appetite, and slow digestion. Clinical data shows it leads to greater weight loss than placebo, semaglutide, and insulin analogs. However, it carries risks of gastrointestinal side effects (nausea, vomiting) and is contraindicated for those with a history of medullary thyroid cancer. Consult a doctor to see if this high-efficacy intervention is appropriate for your specific health profile.
Tirzepatide is a dual incretin agonist... Tirzepatide engages with the GIP receptor more than the GLP-1 receptor... In five clinical studies... patients randomized to receive the recommended dose of tirzepatide (15 mg) had their hemoglobin A1c level lowered by 1.6% more than placebo... The average weight reduction with tirzepatide was 15 pounds greater than placebo... 12 pounds greater than with semaglutide, 29 pounds greater than with insulin degludec, and 27 pounds greater than with insulin glargine.
Why this rating
Based on multiple clinical studies and a NEJM trial, though the authors note methodological limitations (commitment bias, lack of diversity) in the NEJM study.
Source
A new kind of diabetes medication approved by the FDA: is there hope for obesity?
Danisha Dhirani et al. · International Journal of Surgery · 2023
DOI 10.1097/js9.0000000000000044
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →